Needham & Company LLC Reaffirms “Hold” Rating for Regulus Therapeutics (NASDAQ:RGLS)

Needham & Company LLC reaffirmed their hold rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a report published on Tuesday morning, AnalystRatings.com reports.

A number of other brokerages also recently issued reports on RGLS. Wedbush reissued a hold rating and issued a $1.00 price target on shares of Regulus Therapeutics in a report on Thursday, May 16th. Zacks Investment Research downgraded shares of Regulus Therapeutics from a buy rating to a hold rating in a report on Wednesday, July 10th. Finally, ValuEngine raised shares of Regulus Therapeutics from a sell rating to a hold rating in a report on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Regulus Therapeutics presently has an average rating of Hold and an average target price of $1.08.

Shares of Regulus Therapeutics stock opened at $0.56 on Tuesday. Regulus Therapeutics has a 12-month low of $0.50 and a 12-month high of $4.08. The company has a market cap of $11.87 million, a price-to-earnings ratio of -0.10 and a beta of 1.90. The company’s 50-day moving average price is $0.95 and its 200-day moving average price is $1.08.



Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.24. Regulus Therapeutics had a negative net margin of 396.84% and a negative return on equity of 186,717.70%. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $2.50 million. As a group, equities research analysts expect that Regulus Therapeutics will post -2.04 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Wedbush Securities Inc. raised its stake in Regulus Therapeutics by 32.8% in the first quarter. Wedbush Securities Inc. now owns 43,489 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 10,751 shares in the last quarter. Virtu Financial LLC purchased a new stake in Regulus Therapeutics in the first quarter valued at approximately $68,000. CVI Holdings LLC purchased a new stake in Regulus Therapeutics in the second quarter valued at approximately $568,000. Samsara BioCapital LLC purchased a new stake in Regulus Therapeutics in the second quarter valued at approximately $1,131,000. Finally, EcoR1 Capital LLC purchased a new stake in Regulus Therapeutics in the second quarter valued at approximately $1,389,000. 12.72% of the stock is currently owned by institutional investors and hedge funds.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Recommended Story: What is a CD ladder?

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.